source
- Merck ADC, in China study, shows potential to replace chemo in lung cancerThe results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.BioPharma Dive · 16d ago↗ source
- Braveheart, Attovia join next wave of biotech IPOsThe two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.BioPharma Dive · 16d ago↗ source
- J&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsJ&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.